Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Galapagos ( (GLPG) ) has issued an announcement.
On January 5, 2026, Galapagos NV announced that, following completion of required works council consultations in Belgium and the Netherlands, its board has formally decided to wind down the company’s cell therapy activities, a move first signaled on October 21, 2025 after a strategic review and unsuccessful divestment efforts. The shutdown will affect about 365 employees across Europe, the U.S. and China and entail closing facilities in Leiden, Basel, Princeton, Pittsburgh and Shanghai, while the company concentrates resources on its remaining non-cell therapy pipeline, including the GLPG3667 TYK2 program, and seeks to reposition itself for long-term growth through transformational business development, supported by a cash and investment position of roughly €3.0 billion as of December 31, 2025 and a streamlined geographic footprint centered on Mechelen, Chicago and San Francisco.
The most recent analyst rating on (GLPG) stock is a Sell with a $22.00 price target. To see the full list of analyst forecasts on Galapagos stock, see the GLPG Stock Forecast page.
Spark’s Take on GLPG Stock
According to Spark, TipRanks’ AI Analyst, GLPG is a Neutral.
Galapagos’ overall stock score reflects a challenging financial and operational landscape. The company’s strong cash position and strategic partnerships are positive, but are overshadowed by significant operating losses, poor valuation metrics, and technical indicators suggesting potential downward pressure. Investors should be cautious and monitor the company’s ability to execute its strategic transformation and improve financial performance.
To see Spark’s full report on GLPG stock, click here.
More about Galapagos
Galapagos NV is a Belgium-based biopharmaceutical company listed on Euronext and Nasdaq that focuses on discovering, developing and commercializing innovative medicines, with a current emphasis on non-cell therapy programs such as its TYK2 inhibitor GLPG3667 targeting severe autoimmune indications. The company operates from its headquarters in Mechelen, Belgium, and maintains hubs in Chicago and San Francisco in the United States.
Average Trading Volume: 153,109
Technical Sentiment Signal: Buy
Current Market Cap: $2.17B
For detailed information about GLPG stock, go to TipRanks’ Stock Analysis page.